Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:Pooled analysis of randomized trials

Kwok, Chun Shing, Shoamanesh, Ashkan, Copley, Hannah Charlotte, Myint, Phyo Kyaw, Loke, Yoon K. and Benavente, Oscar R. (2015) Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke:Pooled analysis of randomized trials. Stroke, 46. pp. 1014-1023. ISSN 0039-2499

[thumbnail of Lacunar_stroke_manuscript_REF]
PDF (Lacunar_stroke_manuscript_REF) - Accepted Version
Download (937kB) | Preview


Background and Purpose: Lacunar stroke accounts for ≈25% of ischemic stroke, but optimal antiplatelet regimen to prevent stroke recurrence remains unclear. We aimed to evaluate the efficacy of antiplatelet agents in secondary stroke prevention after a lacunar stroke. Methods: We searched MEDLINE, Embase, and the Cochrane library for randomized controlled trials that reported risk of recurrent stroke or death with antiplatelet therapy in patients with lacunar stroke. We used random effects meta-analysis and evaluated heterogeneity with I2. Results: We included 17 trials with 42 234 participants (mean age 64.4 years, 65% male) and follow up ranging from 4 weeks to 3.5 years. Compared with placebo, any single antiplatelet agent was associated with a significant reduction in recurrence of any stroke (risk ratio [RR] 0.77, 0.62–0.97, 2 studies) and ischemic stroke (RR 0.48, 0.30–0.78, 2 studies), but not for the composite outcome of any stroke, myocardial infarction, or death (RR 0.89, 0.75–1.05, 2 studies). When other antiplatelet agents (ticlodipine, cilostazol, and dipyridamole) were compared with aspirin, there was no consistent reduction in stroke recurrence (RR 0.91, 0.75–1.10, 3 studies). Dual antiplatelet therapy did not confer clear benefit over monotherapy (any stroke RR 0.83, 0.68–1.00, 3 studies; ischemic stroke RR 0.80, 0.62–1.02, 3 studies; composite outcome RR 0.90, 0.80–1.02, 3 studies). Conclusions: Our results suggest that any of the single antiplatelet agents compared with placebo in the included trials is adequate for secondary stroke prevention after lacunar stroke. Dual antiplatelet therapy should not be used for long-term stroke prevention in this stroke subtype.

Item Type: Article
Uncontrolled Keywords: antiplatelet agent,aspirin,lacunar stroke,mortality,stroke
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 19 Dec 2015 07:21
Last Modified: 19 Apr 2023 08:22
URI: https://ueaeprints.uea.ac.uk/id/eprint/55812
DOI: 10.1161/STROKEAHA.114.008422

Actions (login required)

View Item View Item